More from the EAU annual meeting in Munich


UroToday has provided a second set of reports on the key presentations given at the annual meeting of the European Association of Urology, being held this year in Munich, Germany. Here again are links to some interesting reports (but do remember that you can only see these reports if you register with UroToday, which is free to users):

In a report on work presented by Gacci et al., UroToday’s correspondent writes that, in their cohort of 1,600 patients, the investigators offered data on the incidence of clinical co-morbidities among patients being treated by treatment location and by type of treatment, as well as on patient quality of life in men being treated for prostate cancer. Both the quantity and the type of those co-morbidities adversely affected the outcomes of treatment.

UroToday states that an unnamed research group identified > 130,000 men aged 40 years and older who had no history of prostate cancer who responded to questions about PSA screening. They were specifically asked about whether they had had an informed decision-making discussion with their doctor(s) about the advantages and disadvantages of PSA testing. Apparently, many more men (58 percent) remembered being counseled about the advantages of testing as opposed to the disadvantages. Only 28 percent remembered being counseled about the latter.

In a third report, UroToday’s correspondent gives data from a presentation dealing with the impact of the USPTF’s 2012 recommendation against routine PSA screening for risk of prostate cancer. This study was based on a cohort of 235,503 men aged ≥ 50 years responding to the 2012 or 2014 Behavioral Risk Factor Surveillance System (BRFSS) surveys. On a national basis, there was a slight overall drop in the total percentage of men being tested in 2014 as opposed to 2012; however, state by state data showed significant differences, with some states showing no change in the likelihood of testing. The researchers also reported no change in prevalence of physician recommendation for PSA screening — despite the 2012 USPSTF statement.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

This site uses Akismet to reduce spam. Learn how your comment data is processed.

%d bloggers like this: